Oncopeptides laboratory


Regulatory status

The regulatory status provides current information on the Company’s marketing authorizations and regulatory submissions.

Read more

Melflufen Access Programs

Oncopeptides has established two programs to enable access to melphalan flufenamide (melflufen) for treatment of eligible patients with multiple myeloma who lack other treatment options, and where melflufen is not yet commercially available and are not to be provided through clinical trials.

Read more about the Access Programs